Elamipretide (SS-31) Benefits: What Studies Report

Elamipretide, also written SS-31, is a short mitochondria-targeted peptide that has been described in the literature as associating with cardiolipin in the inner mitochondrial membrane. A 2025 structured review of its structure, mechanism of action and therapeutic potential described this cardiolipin interaction as the basis for reported effects on membrane organization, electron transport efficiency and reactive oxygen species handling (PMID 39940712). That mechanistic framing matters for reading the rest of this page: most reported outcomes are downstream of mitochondrial bioenergetics rather than of a single organ system.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition or treatment decision. Nothing here describes a protocol, and no outcome is presented as established.

How to Read the Evidence Base

Published elamipretide work falls into several tiers that should not be blended together. Randomized controlled human trials exist in a small number of rare mitochondrial diseases. Open-label extensions follow smaller patient groups over longer periods. Review articles in cardiology and neurology summarize mechanism and trial status. The largest share of literature by volume is animal and cell-culture work across injury and disease models, which cannot be read as evidence of clinical benefit.

Primary Mitochondrial Myopathy: What the Randomized Trial Reported

The most informative human dataset is MMPOWER-3, a randomized clinical trial in individuals with primary mitochondrial myopathy. Researchers reported that the trial did not meet its primary efficacy endpoints, and the publication was framed around efficacy and safety in that population rather than around a positive outcome (PMID 37268435). This is the single most important counterweight to generalized claims about elamipretide improving energy or endurance: in the disease population where the mitochondrial rationale is clearest, the pivotal randomized result was negative on its prespecified primary measures.

Context for that trial comes from reviews of the field. A 2019 review of advances in primary mitochondrial myopathies placed elamipretide among investigational agents being evaluated in this space, where no broadly effective disease-modifying therapy had been established (PMID 31408013). A more recent 2025 review of management advances in mitochondrial myopathies similarly discussed therapeutic candidates against a background of largely supportive care (PMID 40508218).

Why a negative primary endpoint is not the same as "no signal"

Trials in rare mitochondrial disease face small samples, heterogeneous genotypes and endpoint instruments that may not capture what patients experience. Reviewers of the mitochondrial myopathy field have described these measurement and heterogeneity challenges as central obstacles to demonstrating efficacy (PMID 40508218). The appropriate reading is that the primary hypothesis was not confirmed in that trial, not that a mechanism was disproven and not that an effect was shown.

Barth Syndrome: Longer-Term Open-Label Data

Barth syndrome is an X-linked disorder involving the tafazzin gene and abnormal cardiolipin remodeling, which makes it mechanistically adjacent to elamipretide's described cardiolipin interaction (PMID 39940712). Researchers published 168-week open-label extension results from the TAZPOWER study, reporting on long-term efficacy and safety of elamipretide in patients with Barth syndrome over that extended period (PMID 38602181).

Open-label extension data carry well-known interpretive limits: there is no concurrent placebo group, participants and investigators know the assignment, and patients who continue into an extension are often those who tolerated the agent. These constraints apply to the 168-week Barth syndrome extension as published (PMID 38602181). Separately, work on quality of life in Barth syndrome documented the burden experienced by affected individuals and families, which helps explain why patient-reported and functional endpoints are emphasized in this population (PMID 37180415).

Cardiac and Heart Failure Outcomes

Cardiology reviews have treated elamipretide as a representative mitochondria-targeted candidate. A 2022 review on targeting mitochondrial dysfunction with elamipretide summarized the rationale for its use where impaired bioenergetics are thought to contribute to cardiac pathology (PMID 35037146). A companion review on mitochondria as therapeutic targets in heart failure discussed this class of approaches within the broader landscape of heart failure therapeutics (PMID 35147851).

Both are reviews, not outcome trials. Nothing in these publications establishes that elamipretide reduces hospitalization, mortality or other hard cardiovascular endpoints; they describe a mechanistic case and the state of investigation (PMID 35037146, PMID 35147851).

Cell-level cardiac findings

At the bench, a 2025 study described an SS-31 and ferrostatin-1 nanoparticle construct (SS-31@Fer-1) that alleviated ferroptosis in hypoxia/reoxygenation cardiomyocytes through mitochondrial targeting (PMID 39848110). This is an in-vitro result using a combination formulation, so it speaks to mechanism and delivery chemistry rather than to what free peptide does in a patient (PMID 39848110).

Neurological and Injury Models: Animal Evidence Only

A 2023 study in the Journal of Neuroinflammation reported that elamipretide alleviated pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization (PMID 36609266). This was preclinical injury-model work, and researchers described a specific molecular pathway rather than clinical recovery in humans (PMID 36609266). No human spinal cord injury trial appears in the verified literature set for this page, so any extension of that finding to people would be speculation.

Energy, Longevity and Anti-Aging: Where the Evidence Is Thin

Mitochondrial decline is a long-standing theme in aging biology, and a 2025 review examined targeting the electron transport system for enhanced longevity, situating mitochondria-directed interventions within that hypothesis space (PMID 40427507). That review is conceptual; it does not report a human lifespan or healthspan trial of elamipretide (PMID 40427507).

For claims about increased daily energy, improved cognition, skin appearance or general vitality in healthy adults, the verified literature contains no randomized human trial demonstrating those outcomes. The most relevant human efficacy data remain disease-specific, and the pivotal mitochondrial myopathy trial did not meet its primary endpoints (PMID 37268435). Readers encountering general-wellness framing should recognize it as extrapolation from mechanism (PMID 39940712), not as a reported trial result.

Athletic Performance and Musculoskeletal Recovery

A 2026 review in Sports Medicine examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, a category in which many compounds circulate ahead of controlled human data (PMID 41966639). Within the verified set, there is no controlled trial reporting that elamipretide improved strength, endurance, VO2 outcomes or injury recovery in athletes. The absence of such a trial is itself the finding, and the review's framing of unapproved peptide use is the relevant context (PMID 41966639).

Safety and Tolerability: What Studies Report

Safety was a co-primary reporting objective in the human studies. MMPOWER-3 was published as an evaluation of both efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy (PMID 37268435), and the 168-week TAZPOWER open-label extension reported on long-term efficacy and safety in patients with Barth syndrome (PMID 38602181). The 2025 structure-and-mechanism review likewise discussed the therapeutic potential of the peptide alongside its development history (PMID 39940712).

Because this page does not reproduce adverse-event tables that are not within the cited abstracts' scope, the practical takeaway is narrow: safety has been formally assessed in supervised rare-disease trials with defined monitoring (PMID 37268435, PMID 38602181), and nothing in those settings transfers automatically to unsupervised use in healthy people.

Summary of the Reported Evidence

• Mechanism: cardiolipin-targeted action in the inner mitochondrial membrane was described in a 2025 review of structure, mechanism and therapeutic potential (PMID 39940712).
• Strongest randomized human result: primary endpoints were not met in MMPOWER-3 in primary mitochondrial myopathy (PMID 37268435).
• Longest human follow-up: a 168-week open-label extension in Barth syndrome reported long-term efficacy and safety outcomes without a concurrent control group (PMID 38602181).
• Cardiac: reviews described mechanistic rationale in heart failure rather than outcome-trial evidence (PMID 35037146, PMID 35147851).
• Preclinical: pyroptosis reduction in injured rodent spinal cord (PMID 36609266) and ferroptosis reduction in hypoxia/reoxygenation cardiomyocytes using a nanoparticle construct (PMID 39848110).
• Gaps: no verified randomized evidence for general energy, longevity or athletic performance outcomes (PMID 40427507, PMID 41966639).

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (Neurology, 2023)
• Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (Genetics in Medicine, 2024)
• Targeting mitochondrial dysfunction with elamipretide (Heart Failure Reviews, 2022)
• Mitochondria as Therapeutic Targets in Heart Failure (Current Heart Failure Reports, 2022)
• Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization (Journal of Neuroinflammation, 2023)
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting (Biomedicine & Pharmacotherapy, 2025)
• Advances in primary mitochondrial myopathies (Current Opinion in Neurology, 2019)
• Advances in Management of Mitochondrial Myopathies (International Journal of Molecular Sciences, 2025)
• Quality of life in Barth syndrome (Therapeutic Advances in Rare Disease, 2022)
• Targeting the Electron Transport System for Enhanced Longevity (Biomolecules, 2025)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)